Melatonin is one of the most popular sleep-support ingredients in the global supplement market. But if you're planning to launch a melatonin product in the European Union, the regulatory landscape is more complex than you might expect.

The Core Challenge: Novel Food Classification

In the EU, melatonin is classified as a Novel Food under Regulation (EU) 2015/2283. This means any melatonin-containing supplement requires Novel Food authorization before it can be legally marketed — unless it was on the market before May 1997 (the Novel Food cut-off date).

The practical implication: a generic Novel Food application can cost €50,000–€300,000 and take 18–36 months. This is a significant barrier for smaller founder-led brands.

Dosage Limits: A Fragmented Landscape

Even where melatonin is permitted, maximum daily doses vary dramatically:

Member StateMax Daily DoseClassificationNotes
Germany1 mgFood SupplementRequires Novel Food authorization
Spain1.9 mgFood SupplementLimited product categories
Italy1 mgFood SupplementNotification required
France2 mgFood SupplementANSES safety opinion influenced limits
Netherlands0.3 mgFood SupplementVery restrictive
UK (post-Brexit)1 mgFood SupplementGB Novel Foods list applies
Poland1 mgFood SupplementGrowing market, active enforcement

Strategy for Brand Founders

Option 1: Sub-1mg Formulation (Broadest Market Access)

Formulate at ≤0.3mg to cover the most restrictive markets (Netherlands). This limits your efficacy positioning but maximizes regulatory coverage.

Option 2: Multi-SKU Approach

Develop 1mg (core EU), 2mg (France), and 0.3mg (Netherlands) variants. More complex supply chain but allows market-specific claims.

Option 3: Alternative Sleep Ingredients

Consider non-Novel-Food alternatives:

  • Magnesium bisglycinate — Well-established, no Novel Food issues
  • L-theanine — Generally recognized, relaxation positioning
  • Chamomile / Valerian extracts — Traditional use, food ingredient status
  • 5-HTP (Griffonia extract) — Available in several EU markets with less restriction

Enforcement Trends

EU member states have been increasing enforcement on unauthorized melatonin products. In 2025, German authorities issued over 40 warning letters to brands selling melatonin above 1mg or without proper authorization. The days of flying under the radar are ending.

How SuppBridge Helps

We work with regulatory consultants in key EU markets to evaluate your formulation against the latest requirements. For melatonin specifically, we can:

  • Map your target markets against current dosage limits
  • Identify the optimal per-serving dose for maximum EU coverage
  • Connect you with Novel Food application support if needed
  • Recommend alternative ingredient strategies where regulatory barriers are too high

Have questions about EU supplement regulations? Contact our team →

Ready to turn insights into action?

Start a Conversation →